Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.0552W HIGH $1,046.98
Volume
28.46 M
Value Traded
1.36 M
Short % Float
6.36%
-85.92%Week
-81.4%1 Month
-83.53%3 Month
-79.87%6 Month
-100%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
457.47 K
EPS (TTM)
-35.49
P/E Ratio
-
Ent. Value
-18.40 M
Total Shares
1.32 M
Float Shares
1.03 M
Insiders
22.40%
Institutions
0.07%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
SXTC Catalyst Timeline
Dated clinical, regulatory and corporate events for China SXT Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for China SXT Pharmaceuticals, Inc.
25Total events
0Upcoming
0Tier-1 (high impact)
2018 to 2026Coverage
Event history 25
▼Equity OfferingCorporate
Announced $9 million registered direct offering of 4,500,000 units at $2.00 per unit
◆Reverse Stock SplitCorporate
Share Re-classification effective with dual class share structure
▼Equity OfferingCorporate
Announced $10 million registered direct offering of 66,666,666 Class A ordinary shares at $0.15 per share
▼Reverse Stock SplitCorporate
Share consolidation at 1-for-8 ratio to regain Nasdaq minimum bid price compliance
▼Reverse Stock SplitCorporate
One-for-twenty-five reverse stock split effective October 5, 2023
▼Equity OfferingCorporate
Closing of $4.1 million follow-on underwritten offering of ordinary shares and pre-funded warrants with overallotment
▼Equity OfferingCorporate
Pricing of $3.5 million underwritten public offering of ordinary shares and pre-funded warrants
▼Equity OfferingCorporate
Proposed underwritten public offering of ordinary shares and pre-funded warrants
▼Equity OfferingCorporate
Pricing of $15 million PIPE financing with Senior Convertible Notes and Warrants
Past FDA Catalysts and PDUFA Decisions
How SXTC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every SXTC program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SXTC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in SXTC for Q2 2026. | ||||
SXTC Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SXTC ranks across every disease it competes in
Competitive Position is a premium feature
See how SXTC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSXTC News
SXTC▼ -87.8%today
China SXT Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering
China SXT Pharmaceuticals Inc. has announced a $12 million registered direct offering of 8 million Class A ordinary shares at $1.50 each. The offering includes warrants with a similar exercise price, which will be immediately exercisable. The transaction is expected to close on or about October 9, 2026, pending customary closing conditions.
Read more →SXTC▼ -45.6%on this news· ran to -64% by day 3
China SXT Pharmaceuticals, Inc. Announces Share Consolidation
China SXT Pharmaceuticals, Inc. announced a share consolidation of its Class A and B ordinary shares at a 1-for-80 ratio, effective August 10, 2026. Following this consolidation, approximately 1,321,301 Class A shares will be outstanding. The company aims to enhance stock value through this move while continuing to trade on Nasdaq.
Read more →SXTC▼ -83.5%on this news· ran to -97% by day 3
China SXT Pharmaceuticals Inc. Announces $9 Million Registered Direct Offering
China SXT Pharmaceuticals Inc. has announced a registered direct offering to raise approximately $9 million by selling 4.5 million units, each consisting of a Class A ordinary share and a warrant. The offering price is set at $2.00 per unit, with warrants exercisable at $3.20. The transaction is expected to close around July 24, 2025, subject to customary conditions.
Read more →SXTC▲ +5%on this news
China SXT Pharmaceuticals, Inc. Announces Share Re-classification
China SXT Pharmaceuticals, Inc. announced a share re-classification effective March 24, 2026. The company will implement a dual class share structure, creating Class B Ordinary Shares with enhanced voting rights. This change aims to strengthen corporate governance and shareholder engagement. Shareholders holding shares through intermediaries will see automatic adjustments to their holdings.
Read more →SXTC▼ -10.5%on this news
CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC INITIATIVE TO APPLY AI TECHNOLOGY ACROSS THE TCM SUPPLY CHAIN
China SXT Pharmaceuticals, Inc. has announced a strategic initiative to implement AI technology across its Traditional Chinese Medicine supply chain. This initiative aims to enhance supply chain transparency, operational stability, and quality oversight. Key areas of focus include cultivation monitoring, quality evaluation, and supply-demand forecasting, aligning with the company's long-term operational goals.
Read more →SXTC▼ -87.9%on this news
China SXT Pharmaceuticals Inc. Announces $10 Million Registered Direct Offering
China SXT Pharmaceuticals Inc. has announced a definitive agreement for a registered direct offering to raise approximately $10 million by selling 66,666,666 Class A ordinary shares at $0.15 each. The transaction is expected to close around January 12, 2026, subject to customary closing conditions. Univest Securities, LLC is acting as the sole placement agent for this offering, which is being made under a previously filed shelf registration statement with the SEC.
Read more →SXTCCHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC AI INSIGHTS INITIATIVE TO OPTIMIZE TRADITIONAL CHINESE MEDICINE PORTFOLIO, ENHANCE MARKET ANALYSIS AND EXPLORE AI-SUPPORTED CLINIC DEPLOYMENT
China SXT Pharmaceuticals, Inc. has announced the launch of a Strategic AI Insights Initiative aimed at enhancing its Traditional Chinese Medicine (TCM) portfolio through AI-driven analytics. The initiative focuses on improving product planning and market intelligence, with the goal of aligning with evolving consumer demands. As part of this strategy, the company will develop AI-supported consultation stores across China to provide personalized health screenings and product recommendations. The integration of these AI technologies is expected to bolster the company's R&D efforts and adapt to market changes effectively.
Read more →SXTCMANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our results of operations and financial condition should be read together with our unaudited
The article discusses the financial condition and operational results of China SXT Pharmaceuticals, Inc. It highlights their organizational structure involving a variable interest entity in China, through which they conduct their business. However, significant risks are noted concerning compliance with PRC laws and regulations, particularly affecting their ability to distribute dividends to shareholders. The content further emphasizes the uncertainties that may impact the company's operations and financial performance due to governmental regulations.
Read more →SXTCCHINA SXT PHARMACEUTICALS, INC. (incorporated in the British Virgin Islands with limited liability) (NASDAQ: SXTC) NOTICE OF 2025 SPECIAL MEETING OF SHAREHOLDERS To be held on
China SXT Pharmaceuticals, Inc. has announced a special meeting for shareholders scheduled for July 28, 2025. The primary agenda will include a proposal to amend the company's memorandum and articles of association to implement a dual class share structure. Shareholders of record as of July 9, 2025, will be able to vote on this important governance change. The meeting will take place at the company's office in Jiangsu, China.
Read more →SXTCChina SXT Pharmaceuticals Has Regained Compliance with Nasdaq’s Minimum Bid Price Deficiency
China SXT Pharmaceuticals has regained compliance with Nasdaq's minimum bid price requirement after receiving a Compliance Notice. The company had previously been notified of a deficiency but managed to meet the requirement by maintaining a closing bid price of at least $1.00 per share for 10 consecutive business days. This compliance matter is now closed.
Read more →SXTCWARRANT EXCHANGE AGREEMENT This Warrant Exchange Agreement (this " Agreement ") between China SXT Pharmaceuticals, Inc. (the " Company ") and the undersigned hereto (each, a " Holder ", collectively, the " Holders "; tog
China SXT Pharmaceuticals Inc. has initiated a Warrant Exchange Agreement dated March 13, 2025, to cancel 28,400,000 existing warrants in favor of 11,225,000 new ordinary shares. This transaction is being executed under the exemption from registration as provided by the Securities Act of 1933. The agreement indicates a strategic decision by the company to streamline its equity instruments, potentially making it more attractive to investors. Both the company and the investors involved are expected to benefit from this exchange.
Read more →SXTCEMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the " Agreement" ), is entered into as of [ ] (the " Effective Date "), by and between China SXT Pharmaceuticals, Inc., incorporated under the laws of the British Virgin Is
China SXT Pharmaceuticals, Inc. has entered into an employment agreement with Simon Lim Sze Beng, designating him as Co-CEO. The initial employment term is set for five years, subject to automatic renewals unless a notice is provided. The agreement outlines comprehensive termination conditions, including for cause and without cause, as well as severance payments and benefits. Additionally, Clauses regarding conduct during employment are included, indicating a structured governance approach.
Read more →SXTCSECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this " Agreement ") is dated as of
China SXT Pharmaceuticals, Inc. entered into a Securities Purchase Agreement dated January 21, 2025. The agreement involves the issuance and sale of securities to identified purchasers under specific conditions. It includes key definitions of terms related to the purchase, including 'Shares' and 'Warrant Shares,' as well as the legal framework under which this agreement operates. The transaction aims to secure necessary funding for the Company's future business activities.
Read more →SXTCChina SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency
China SXT Pharmaceuticals, Inc. received a notification from Nasdaq regarding a bid price deficiency, as its stock price has been below $1.00 for 30 consecutive business days. The company has until April 1, 2025, to regain compliance with Nasdaq's minimum bid price requirements. If compliance is not achieved, the company may seek an additional 180 days to address the issue.
Read more →SXTCChina SXT Pharmaceuticals, Inc. Regained Compliance with Nasdaq’s Minimum Bid Price Rule
China SXT Pharmaceuticals, Inc. announced that it has regained compliance with Nasdaq's minimum bid price rule after its ordinary shares closed at $1.00 or greater for ten consecutive days. This determination was communicated by Nasdaq on October 19, 2023, which closed the matter regarding the company's listing status. SXT Pharmaceuticals specializes in the development and marketing of Traditional Chinese Medicine Pieces and remains committed to innovation in this field.
Read more →About China SXT Pharmaceuticals, Inc.
BIOPHARMAWATCH ELITE PLUS
Trade the next SXTC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime